Collaboration with Myositis Canada

B-TEMIA and Myositis Canada agreed to collaborate to promote access to the Keeogo Powered Walking Assistance Device and the cause of Myositis.

Who is Myositis Canada?

Myositis Canada is a voluntary charitable organization dedicated to improving the lives of people with myositis. Their goal is to support as many people with myositis as caregivers, researchers and health care providers in diagnosing, treating and rehabilitating the disease.

What is Myositis?

The word Myositis literally means inflammation of muscle; it describes inflammation or swelling of the muscle tissue that can result in rapid and tragic muscle loss. It is considered a rare disease and its causes are still largely unknown. There are a number of types of Myositis; they include:

  • Dermatomyositis (DM)
  • Inclusion-Body Myositis (IBM)
  • Polymyositis (PM)
  • Juvenile forms of Myositis (JM)

Treatment and response to treatment varies for each disease type. For more information:

How can the Keeogo Dermoskeleton help people affected by Myositis?

The Keeogo device can be worn to compensate loss of muscular strength associated with Myositis. It was demonstrated through numerous field trials, clinical trials and biomechanical and physiological assessments that Keeogo can enhance the ability to walk, increase balance and stability, reduce compensatory movements, reduce pain, and improve kinetics and kinematics.

Keeogo can help people affected by Myositis stay active longer, improve accessibility and independence, and delay the use of a wheelchair. Martin Jarry, affected by inclusion body myositis, trained and ran a 10Km with the Dermoskeleton at the Tamarack Race Weekend in Ottawa in May 2017.

The actual benefits may vary from person to person. This is why B-TEMIA offers a clinical evaluation and a three-week trial at home before deciding to purchase the device for the longer term.

People affected by Myositis who are interested in trying Keeogo should contact Myositis Canada for access to the special arrangements in collaboration with the B-TEMIA.